These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18228182)

  • 41. Development of a Vero cell-derived influenza whole virus vaccine.
    Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
    Dev Biol Stand; 1999; 98():101-10; discussion 111. PubMed ID: 10494963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system.
    Pillay S; Meyers A; Williamson AL; Rybicki EP
    Biotechnol Prog; 2009; 25(4):1153-60. PubMed ID: 19572400
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.
    Shoji Y; Bi H; Musiychuk K; Rhee A; Horsey A; Roy G; Green B; Shamloul M; Farrance CE; Taggart B; Mytle N; Ugulava N; Rabindran S; Mett V; Chichester JA; Yusibov V
    Vaccine; 2009 Feb; 27(7):1087-92. PubMed ID: 19100806
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin.
    Schwarzer J; Rapp E; Hennig R; Genzel Y; Jordan I; Sandig V; Reichl U
    Vaccine; 2009 Jul; 27(32):4325-36. PubMed ID: 19410619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strain identification of commercial influenza vaccines by mass spectrometry.
    Creskey MC; Smith DG; Cyr TD
    Anal Biochem; 2010 Nov; 406(2):193-203. PubMed ID: 20667441
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epitope-based vaccine against influenza.
    Ben-Yedidia T; Arnon R
    Expert Rev Vaccines; 2007 Dec; 6(6):939-48. PubMed ID: 18034655
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prospects and achievements of genetic engineering in development of antiviral vaccines].
    Tikhonenko TI
    Mol Biol (Mosk); 1984; 18(1):176-88. PubMed ID: 6323971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys.
    Fu TM; Grimm KM; Citron MP; Freed DC; Fan J; Keller PM; Shiver JW; Liang X; Joyce JG
    Vaccine; 2009 Feb; 27(9):1440-7. PubMed ID: 19146898
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Aug; 7(6):713-9. PubMed ID: 18665769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Developments of subunit and VLP vaccines against influenza A virus.
    Deng MP; Hu ZH; Wang HL; Deng F
    Virol Sin; 2012 Jun; 27(3):145-53. PubMed ID: 22684468
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Research progress and prospect of universal influenza vaccine].
    Luo DY; Xue CY; Cao YC
    Bing Du Xue Bao; 2013 Nov; 29(6):646-50. PubMed ID: 24520771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
    Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
    Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Large scale production and downstream processing of a recombinant porcine parvovirus vaccine.
    Maranga L; Rueda P; Antonis AF; Vela C; Langeveld JP; Casal JI; Carrondo MJ
    Appl Microbiol Biotechnol; 2002 Jun; 59(1):45-50. PubMed ID: 12073130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Large-scale production and purification of VLP-based vaccines.
    Vicente T; Roldão A; Peixoto C; Carrondo MJ; Alves PM
    J Invertebr Pathol; 2011 Jul; 107 Suppl():S42-8. PubMed ID: 21784230
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine).
    Mabrouk T; Ellis RW
    Dev Biol (Basel); 2002; 110():125-34. PubMed ID: 12477315
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Translational research on vaccines: influenza as an example.
    Belshe RB
    Clin Pharmacol Ther; 2007 Dec; 82(6):745-9. PubMed ID: 17971813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and strategies of cell-culture technology for influenza vaccine.
    Feng SZ; Jiao PR; Qi WB; Fan HY; Liao M
    Appl Microbiol Biotechnol; 2011 Feb; 89(4):893-902. PubMed ID: 21063703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.